Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Eli Lilly will present new data across its cardiometabolic portfolio at the EASD 2026 annual meeting in Milan, September 28 to October 2, covering retatrutide, Foundayo (orforglipron), eloraTZP, and its tirzepatide franchises Zepbound and Mounjaro. Pivotal Phase 3 TRIUMPH-2 data show retatrutide, a triple GIP/GLP-1/glucagon agonist, delivered weight loss of up to 20.8% (49.6 lbs / 22.5 kg) and A1C reductions of up to 1.6% at 80 weeks in adults with obesity or overweight and type 2 diabetes.
Key figures
- Drug Name
- retatrutide; Foundayo (orforglipron); eloraTZP (eloralintide + tirzepatide)
- Phase Of Trial
- Phase 3 (TRIUMPH-2, ACHIEVE-4); Phase 2 (eloraTZP)
- Achieve4 mace3 hr
- 0.77
- Achieve4 mace4 hr
- 0.84
- Surpass cvot mace3 hr
- 0.92
- Retatrutide weight loss
- up to 49.6 lbs (22.5 kg; 20.8%) at 80 weeks
- Retatrutide a1c reduction
- up to 1.6% at 80 weeks
- Eloratzp phase1 weight loss
- 17% at 16 weeks vs 10% for tirzepatide 5 mg alone
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.